Gene editing therapy may permanently inseal the cancer cells

A study by Tel Aviv University in Israel has shown that the CRISPR/Cas9 system is very effective in treating invasive cancers, an important step in finding a cure for cancer, Science Advances reported.
a new delivery system, CRISPR-LNP, based on lipid nanoparticles, developed by researchers in the United States, can target cancer cells and destroy them through genetic action. The system carries a genetic messenger (messenger RNA) that encodes CRISPR enzyme Cas9, a molecular scissors that cut the DNA of cancer cells as a cut cell DNA, disabling it and permanently preventing replication.

dan Peel, associate director of research and development at Tel Aviv University's School of Biomedical and Cancer Research, said it was the first study in the world to demonstrate that CRISPR genome editing systems can be used to effectively treat cancer in living animals. The method is not chemotherapy and has no side effects, and cancer cells treated with this method will never be active again.
to test the feasibility of using the technique to treat cancer, Professor Peel and his team chose two of the deadliest cancers, glioblastoma and metastatic ovarian cancer.
glioblastoma is the most invasive type of brain cancer, with a life expectancy of 15 months and a five-year survival rate of only 3%. Studies have shown that a single treatment using CRISPR-LNP can double the average life expectancy of mice with glioblastoma, thus increasing their total survival rate by about 30%.
ovarian cancer is one of the leading causes of female mortality and the deadliest cancer in the female reproductive system. When metastasis spreads throughout the body, most patients are diagnosed with advanced cancer. Despite advances in treatment in recent years, only one-third of patients are likely to survive. Studies have shown that the use of CRISPR-LNP for treatment in metastatic ovarian cancer mouse models can improve their overall survival rate by 80%.
Professor Napier says CRISPR genome editing, which identifies and alters any gene fragment, revolutionises the ability to destroy, repair and even replace genes in a personalized way. Despite the wide range of applications of this technology, its clinical practice is still in its infancy and it is urgent to develop an effective delivery system to deliver CRISPR safely and accurately to target cells. A delivery system developed by new research could target DNA responsible for cancer cell survival, an innovative approach to invasive cancers that currently do not have an effective treatment.
researchers point out that by demonstrating its potential in treating two types of invasive cancers, the technology opens up many new possibilities for treating other types of cancer, as well as rare genetic and chronic viral diseases such as
.